Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alvimopan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2017
Lead Product(s) : Alvimopan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvimopan Use in Polytraumatized Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2017
Lead Product(s) : Alvimopan
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Alvimopan in Major Spine Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2016
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Alvimopan as Rescue in Post op Ileus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2016
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2015
Lead Product(s) : Alvimopan
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Accelerating Gastrointestinal Recovery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2012
Lead Product(s) : Alvimopan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvimopan
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Entereg Laparoscopic Colon Resection Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2010
Lead Product(s) : Alvimopan
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable